Evaxion enters new partnership: Danish Biotech Weekly (39)

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Evaxion Biotech entered a partnership regarding a vaccine against gonorrhea, Ascendis Pharma presented results of a trial with TransCon, and ViroGates announced positive results from a clinical trial suPAR-guided antibiotec treatment in sepsis.

The past week was another week full of exciting news with 8 of the 20 listed Danish biotech companies publishing news. 11 of the 20 companies had a positive share price development the past week and 8 companies have a positive share price performance year to date. Cessatech continues to be the best performing stock year-to-date.

Company news the past week

Ascendis Pharma

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency (Link)


No news the past week


Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001 (Link)

CS Medica

No news the past week


No news the past week

Evaxion Biotech

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company (Link)

Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea (Link)


Last day of trading in warrants of series TO 8 in Expres2ion Biotechnologies 18 September 2023 (Link)


No news the past week


No news the past week


No news the past week

Initiator Pharma

Initiator Pharma announces indication expansion – clinical drug candidates active in models of female sexual dysfunction (Link)

IO Biotech

No news the past week

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week


ViroGates announces positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis presented today at the European Shock Conference in Vienna, Austria (Link)

Zealand Pharma

Zealand Pharma A/S – admittance to trading and official listing of new shares due to exercise of employee warrants (Link)

Y-mAbs Therapeutics

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology (Link)


No news the past week



On average, the Danish biotech stocks delivered a positive share price performance last week of 4.8%. Biosergen rose 77% without even announcing any news. ViroGates followed with a 24% increase after announces positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis. Notably, Evaxion only rose 4% after expanding preclinical bacterial pipeline with a leading pharmaceutical company as well as entered a partnership to develop a vaccine against gonorrhea. On the other hand, Ascendis Pharma fell the most with a 7% decrease following results of a trial with TransCon. The best stocks year-to-date include Curasight, Cessatech Fluoguide, and Saniona after soaring 87-154%. Overall, the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 3.3%. However, it is driven by the few companies delivering very positive returns.

Read more about Curasight (in Danish): Et succesfuldt kvartal for Curasight med mere i vente

Overview of share price developments the past week, year-to-date and last twelve months


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.